Urinary iron excretion induced by intravenous infusion of deferoxamine in ß-thalassemia homozygous patients

Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients.

The purpose of the present study was to identify noninvasive methods to evaluate the severity of iron overload in transfusion-dependent beta-thalassemia and the efficiency of intensive intravenous therapy as an additional tool for the treatment of iron-overloaded patients. Iron overload was evaluated for 26 beta-thalassemia homozygous patients, and 14 of them were submitted to intensive chelati...

The Comparison of Efficacy of Original Brand Deferoxamine with Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients with Thalassemia Major

Background: Deferoxamine mesylate is still the conventional and well-known iron chelator for patients with thalassemia major. However, due to some marketing issues the well-known original brand, Desferal®, produced by Novartis Pharmaceuticals Company is not as available as before. The generic brands of Deferoxamine have been introduced in many parts of the world including Iran; however, they ar...

Urinary oxalate excretion during intravenous infusion of diuretics in man.

Aminophylline Infusion Induced Excretion of Magnesium During Magnesium Loading Test in Critically Ill Patients

      The aim of this study was to investigate the prevalence of Mg deficiency and effect of aminophylline infusion on urine magnesium concentration after magnesium loading test (MLT). To determine serum Mg, venous blood specimens were obtained just before the first MLT. Two MLTs were performed. The first one was done before starting aminophylline infusion and the 2nd one was done du...

Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.

Several life-threatening complications of the common disorder sickle cell disease require management with red blood cell transfusions and, hence, long-term iron-chelating therapy. The efficacy of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) has not previously been determined in patients with sickle cell disease. We compared the efficacy of L1 to that of standard-dose subcutaneo...